Description

Product Description

Bevacizumab (CAS 216974-75-3) is a recombinant humanized monoclonal antibody specifically targeting vascular endothelial growth factor A (VEGF-A), a key mediator of angiogenesis and vascular permeability. By binding to VEGF-A, Bevacizumab prevents its interaction with VEGF receptors on endothelial cells, inhibiting downstream signaling cascades involved in angiogenic processes.

In preclinical research, Bevacizumab is used to study mechanisms of tumor angiogenesis, vascular remodeling, and VEGF-dependent cell signaling. It is particularly valuable in evaluating the role of VEGF-A in cancer progression, endothelial cell proliferation, and migration in both in vitro and in vivo models. By blocking VEGF-A, researchers can examine changes in microvascular density, vessel maturation, and tumor microenvironment interactions.

Bevacizumab’s high specificity allows mechanistic studies without significant off-target effects. Researchers employ it to investigate:

• VEGF-mediated angiogenesis in tumor and normal tissue models.

• Endothelial cell proliferation, migration, and tube formation assays.

• Tumor progression and vascularization in xenograft and syngeneic animal models.

• Synergistic or combinatorial effects with chemotherapy or other targeted therapies.

The antibody is provided as a lyophilized, high-purity powder (≥99%), suitable for laboratory research. It is soluble in PBS or other physiological buffers, facilitating in vitro and in vivo applications. Each batch is verified using ELISA, SDS-PAGE, and Western blot to confirm activity, purity, and structural integrity.

Bevacizumab is also utilized as a mechanistic probe to explore VEGF-A-dependent signaling, including the PI3K/AKT, MAPK/ERK, and NF-κB pathways. Preclinical studies can leverage this compound to model anti-angiogenic therapy, evaluate compensatory vascular signaling, and investigate endothelial cell responses in tumor and tissue microenvironments.

Its application extends to research on vascular biology, tumor microenvironment modulation, and translational studies evaluating novel anti-angiogenic strategies. Bevacizumab’s specificity, reproducibility, and high purity make it an essential reagent for mechanistic studies in oncology and angiogenesis research.

Product Specifications

Mechanism of Action

Bevacizumab is a recombinant humanized monoclonal antibody that specifically binds to vascular endothelial growth factor A (VEGF-A), preventing it from interacting with VEGF receptors (VEGFR-1 and VEGFR-2) on endothelial cells.

This blockade inhibits VEGF-mediated signaling pathways, including PI3K/AKT, MAPK/ERK, and NF-κB, leading to reduced endothelial cell proliferation, migration, and tube formation. In preclinical cancer models, this mechanism suppresses angiogenesis, tumor microvascular density, and vascular permeability, making Bevacizumab a critical tool for studying VEGF-dependent processes and anti-angiogenic therapies.

Side Effects

For laboratory use, handle Bevacizumab with standard precautions:

• Avoid inhalation, ingestion, and skin or eye contact.

• Use gloves, lab coat, and protective eyewear.

• Perform experiments in a well-ventilated area or biosafety cabinet.

• Dispose of contaminated materials following institutional safety guidelines.

Experimental endpoints may include inhibition of endothelial proliferation or vascular remodeling in vitro or in vivo. This product is for research use only.

Keywords

Bevacizumab, CAS 216974-75-3, VEGF inhibitor, anti-VEGF antibody, angiogenesis research, tumor progression, endothelial cell signaling, monoclonal antibody, recombinant humanized antibody, high purity, ≥99% purity, factory peptide supplier, peptide wholesale China, China peptide manufacturer, OEM & bulk peptide production.

Shipping Guarantee

All Bevacizumab shipments are managed using validated cold-chain logistics to maintain antibody stability. Lyophilized powders are sealed in moisture-proof, light-protected containers with secondary protective wrapping. Packages include full tracking and insurance coverage to ensure safe delivery worldwide.

Trade Assurance

Bevacizumab Product authenticity and analytical verification are guaranteed via ELISA, SDS-PAGE, and Western blot. Each batch includes a Certificate of Analysis (CoA) confirming ≥99% purity. Replacement or refund is provided for any deviation from listed specifications.

Payment Support

Accepted global payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are encrypted and verified for confidentiality and security.

Disclaimer

This Bevacizumab product is intended for laboratory research use only. It is not for human or veterinary administration. Researchers must follow appropriate safety protocols. Data generated with Bevacizumab should not be interpreted as clinical evidence or therapeutic guidance.

References

1. PubChem Database: Bevacizumab (CID 24757)

2. ChEMBL Database: Bevacizumab Bioactivity Summary (ChEMBL ID CHEMBL1201581)

3. DrugBank: Bevacizumab – DB00356 (Mechanism and Pharmacology Data)

4. PubMed ID 19075214 – VEGF blockade and angiogenesis in preclinical models

5. IUPHAR/BPS Guide to Pharmacology: VEGF inhibitors and selectivity profiles